FDA Clears Voyager's IND for Alzheimer's Candidate VY1706, Dosing Set for H2 2026

On June 2, 2026, Voyager Therapeutics Inc. (NASDAQ: VYGR) announced the U.S. Food and Drug Administration cleared its investigational new drug application for VY1706, an experimental Alzheimer's disease therapy, enabling a first-in-human clinical trial. The company plans to begin dosing patients in the second half of 2026. VY1706 targets tau protein aggregates, a hallmark of Alzheimer's pathology. The Phase 1 study will assess safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with early-stage Alzheimer's. Voyager did not disclose financial details of the program. The IND clearance removes a key regulatory hurdle for Voyager's pipeline, which uses a proprietary vectorized antibody platform to deliver therapies across the blood-brain barrier. Alzheimer's remains a competitive field with limited disease-modifying treatments. Further trial design specifics are expected later this year.